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Many	  researchers	  and	  clinicians	  are	  interested	  in	  how	  a	  patient’s	  individual	  genetic	  
makeup	  could	  predict	  the	  appropriate	  medication	  and	  dose	  for	  that	  patient.	  The	  tailoring	  of	  
prescribing	  practices	  to	  an	  individual	  patient	  has	  been	  coined	  personalized	  medicine,	  and	  
incorporating	  genetic	  information	  into	  the	  prediction	  is	  called	  pharmacogenetics.	  One	  way	  
to	  predict	  drug	  response,	  or	  efficacy,	  is	  by	  looking	  at	  enzymes	  within	  the	  liver	  that	  
metabolize,	  or	  break	  down,	  drugs.	  Many	  of	  these	  enzymes	  belong	  to	  a	  class	  called	  the	  
Cytochrome	  P450s	  (CYPs).	  Specifically,	  two	  closely	  related	  enzymes,	  CYP3A4	  and	  CYP3A5,	  
are	  involved	  in	  metabolizing	  50%	  of	  drugs	  currently	  on	  the	  market	  (eg:	  statins,	  
antiepileptics,	  anticancer	  agents,	  and	  antidepressants).	  Within	  the	  genes	  that	  code	  for	  these	  
enzymes,	  there	  are	  single	  nucleotide	  polymorphisms	  (SNPs),	  which	  are	  single	  base	  pair	  
changes	  in	  the	  DNA.	  SNPs	  can	  change	  the	  rate	  of	  metabolism	  of	  drugs,	  toxins,	  and	  
compounds	  found	  naturally	  in	  the	  body.	  However,	  with	  interest	  in	  personalized	  medicine	  
on	  the	  rise,	  some	  populations,	  who	  experience	  health	  disparities	  or	  are	  medically	  
underserved,	  are	  not	  always	  included	  in	  research,	  and	  therefore,	  not	  benefiting	  from	  
genetic-­‐guided	  therapies.	  We	  previously	  completed	  a	  study	  with	  participants	  from	  the	  
Confederated	  Salish	  and	  Kootenai	  Tribes	  (CSKT),	  located	  on	  the	  Flathead	  Reservation	  in	  
northwest	  Montana.	  Select	  CYP	  enzymes	  were	  genotyped,	  including	  CYP3A4	  and	  CYP3A5.	  
Most	  SNPs	  identified	  in	  the	  CSKT	  participants	  were	  found	  at	  frequencies	  similar	  to	  those	  
reported	  in	  European-­‐descended	  populations.	  Interestingly,	  one	  specific	  SNP,	  called	  
CYP3A4*1G,	  was	  discovered	  at	  a	  high	  allele	  frequency	  (26.81%	  in	  CSKT	  compared	  to	  8.3%	  
in	  Europeans).	  These	  allele	  frequencies	  mean	  that	  approximately	  7%	  of	  the	  CSKT	  
population	  carry	  two	  copies	  of	  the	  SNP	  while	  approximately	  39%	  carry	  one	  copy.	  The	  
physiological	  significance	  of	  this	  SNP	  is	  unclear	  as	  there	  are	  limited	  and	  confounding	  data,	  
however,	  most	  of	  the	  data	  published	  to	  date	  suggests	  that	  the	  SNP	  causes	  decreased	  
metabolism	  of	  drugs.	  Clinically,	  this	  could	  result	  in	  a	  need	  for	  a	  decreased	  dose	  of	  
medication.	  In	  addition,	  this	  CYP3A4	  SNP	  was	  observed	  to	  be	  often	  inherited	  with	  another	  
SNP	  in	  the	  related	  CYP3A5	  gene,	  called	  CYP3A5*3,	  which	  encodes	  for	  a	  nonfunctional	  
enzyme.	  These	  SNPs	  found	  in	  the	  CSKT	  are	  of	  particular	  interest,	  because	  inheriting	  these	  
two	  SNPs	  together	  could	  cause	  drastic	  changes	  in	  drug	  metabolism	  since	  the	  two	  enzymes	  
metabolize	  many	  of	  the	  same	  drugs.	  We	  propose	  that	  the	  CYP3A4*1G	  SNP	  results	  in	  a	  
decrease	  in	  clearance	  via	  drug	  metabolism	  of	  CYP3A4	  substrates.	  We	  are	  using	  human	  B-­‐
lymphocyte	  cells	  to	  assess	  CYP3A4	  enzyme	  function	  and	  total	  enzyme	  content.	  We	  have	  
selected	  B-­‐lymphocyte	  cells	  from	  the	  Coriell	  Cell	  Repository	  that	  differ	  only	  by	  CYP3A4	  
genotype.	  The	  CYP3A4	  genotype	  of	  the	  three	  cell	  lines	  are	  *1/*1	  (wild-­‐type),	  *1/*1G,	  and	  
*1G/*1G.	  To	  control	  for	  the	  CYP3A5	  genotype,	  all	  cells	  were	  selected	  based	  on	  a	  *1/*1	  
CYP3A5	  genotype.	  In	  addition	  to	  B-­‐lymphocyte	  samples,	  we	  will	  also	  investigate	  CYP3A4*1G	  
activity	  and	  content	  in	  liver	  microsome	  samples	  from	  the	  University	  of	  Washington	  School	  
of	  Pharmacy	  Liver	  Bank.	  The	  livers	  have	  *1/*1,	  *1/*1G,	  and	  *1G/*1G	  genotypes	  of	  CYP3A4.	  
However,	  due	  to	  the	  limited	  sample	  of	  livers,	  we	  will	  not	  be	  able	  to	  control	  for	  CYP3A5,	  and	  
the	  samples	  will	  have	  variable	  CYP3A5	  genotypes.	  To	  evaluate	  enzyme	  function	  in	  both	  the	  
B-­‐lymphocytes	  and	  liver	  microsomes,	  we	  will	  use	  a	  P450-­‐Glo™	  Assay.	  This	  assay	  produces	  
light	  which	  will	  be	  measured	  by	  a	  luminometer.	  The	  amount	  of	  light	  emitted	  is	  
proportional	  to	  CYP3A4	  enzyme	  activity.	  Lymphocyte	  and	  microsomal	  CYP3A4	  and	  
CYP3A5	  protein	  content	  will	  be	  measured	  by	  Western	  Blot	  using	  specific	  CYP3A4	  and	  
CYP3A5	  antibodies.	  Also,	  CYP3A4	  and	  CYP3A5	  mRNA	  levels	  will	  be	  quantitated	  by	  real	  time	  
PCR.	  We	  expect	  to	  find	  that	  samples	  with	  CYP3A4*1G/*1G	  genotypes	  will	  have	  a	  slower	  
maximum	  rate	  of	  metabolism	  than	  cell	  lines	  with	  CYP3A4*1/*1	  genotype.	  This	  is	  due	  to	  the	  
expectation	  that	  *1G	  carriers	  will	  have	  less	  CYP3A4	  protein	  content	  than	  the	  wild-­‐type	  
samples.	  Also,	  we	  expect	  that	  binding	  affinity	  between	  the	  enzyme	  and	  medications	  will	  
remain	  unchanged	  between	  genotypes	  due	  to	  the	  intronic	  location	  of	  the	  SNP.	  These	  
findings	  will	  be	  important	  because	  they	  could	  help	  guide	  clinicians	  in	  proper	  treatments	  for	  
the	  CSKT	  population	  who	  carry	  the	  variant	  allele.	  Our	  goal	  is	  to	  decipher	  the	  impact	  of	  the	  
CYP3A4*1G	  SNP	  and	  the	  metabolic	  consequences	  of	  inheriting	  it	  with	  CYP3A5*3.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
